Michael J Lacy

US Patent:

20100310593, Dec 9, 2010

Filed:

Jun 16, 2008

Appl. No.:

12/664554

Inventors:

So-ching Brazer - Leesburg VA, US
James Adam Crawford - Dublin OH, US
Chunghee Lee - Clarksburg MD, US
Sukjoon Park - Germantown MD, US
W. James Jackson - Marriottsville MD, US
Michael Joseph Lacy - Damascus MD, US
Hang Lu - Gaithersburg MD, US

Assignee:

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. - Gaithersburg MD

International Classification:

A61K 39/02
C07H 21/04
C12N 15/63
C12N 1/21
C07K 14/295
A61K 48/00
A61K 38/16
A61P 31/04

US Classification:

4241901, 536 237, 4353201, 43525233, 530350, 514 44 R, 514 212

Abstract:

The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a infection. The present invention is also directed toward an isolated nucleic acid encoding a polypeptide comprising at least 70% identity to any one of SEQ ID NOS: 2, 11, 13, 19, or 21, wherein the polypeptide is soluble in the absence of denaturing agents. In some aspects of the invention, the polynucleotide is codon-optimized. In some embodiments, the present invention is related to the polypeptide encoded by the polynucleotide of the invention. Administration of polypeptides of the present invention can be used as a method to treat or prevent a infection in an animal in need thereof.

US Patent:

20110268760, Nov 3, 2011

Filed:

Jun 16, 2009

Appl. No.:

12/999246

Inventors:

Jonathan Lewis Telfer - Berkshire, GB
Mark Richard Redfern - Berkshire, GB
Michael Joseph Lacy - Gaithersburg MD, US

International Classification:

A61K 39/118
A61P 31/04
A61P 37/04
C12N 1/21

US Classification:

4242001, 4352523

Abstract:

The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide.

US Patent:

20130115234, May 9, 2013

Filed:

Mar 28, 2011

Appl. No.:

13/637305

Inventors:

Tina Guina - Silver Spring MD, US
Michael Lacy - Damascus MD, US
Mario Skiadopoulos - Potomac MD, US
Nutan Mytle - Gaithersburg MD, US

Assignee:

Emergent Product Development Gaithersburg,Inc. - Gaithersburg MD

International Classification:

A61K 39/145

US Classification:

4241861, 4353201, 435349, 435325, 435366, 435 693, 435239, 536 2372, 536 232

Abstract:

The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.